2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

近年来, 对不稳定性心绞痛(unstable angina, UA) 和非ST 段抬高心肌梗死(non-ST-elevation
myocardial infarction, NSTEMI) 病理生理机制的认识逐步深入, 有关大规模临床试验结果陆续 …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …

Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Owing to the constantly evolving nature of the medical literature, the Society of Thoracic
Surgeons (STS) clinical practice guidelines periodically undergoes evaluation and updating …

Objective To assess the risks and benefits of P2Y 12 inhibitor monotherapy compared with
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …

Endothelial cells (ECs) constitute the innermost layer in all blood vessels to maintain the
structural integrity and microcirculation function for coronary microvasculature. Impaired …